DB
ORIC icon

Dmitry Balyasny’s Oric Pharmaceuticals ORIC Stock Holding History

Dmitry Balyasny’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$262K Sell
24,201
-499,589
-95% -$4.53M ﹤0.01% 2746
2026
Q1 		$6.64M Sell
523,790
-426,424
-45% -$4.84M 0.01% 1238
2025
Q4 		$7.77M Sell
950,214
-569,100
-37% -$6.55M 0.01% 1160
2025
Q3 		$18.2M Sell
1,519,314
-258,430
-15% -$2.72M 0.02% 759
2025
Q2 		$18M Sell
1,777,744
-229,528
-11% -$1.54M 0.03% 707
2025
Q1 		$11.2M Buy
2,007,272
+452,012
+29% +$3.95M 0.02% 855
2024
Q4 		$12.6M Buy
1,555,260
+424,194
+38% +$3.89M 0.02% 868
2024
Q3 		$11.6M Buy
+1,131,066
New +$11.2M 0.02% 869
2023
Q2 		– Sell
-11,725
Closed -$66.8K – 2648
2023
Q1 		$66.8K Buy
+11,725
New +$61.3K ﹤0.01% 2355
2022
Q4 		– Sell
-13,557
Closed -$43K – 3109
2022
Q3 		$43K Buy
+13,557
New +$54.3K ﹤0.01% 2492

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dmitry Balyasny's ORIC Position: Q2 2026 in Review

Dmitry Balyasny reduced its Oric Pharmaceuticals (ORIC) stake by 95% in Q2 2026, selling an estimated $4.53M and leaving 24,201 shares worth $262K. The position accounts for ﹤0.01% of the portfolio, ranked #2746.

Dmitry Balyasny first reported a position in ORIC in Q3 2022 and has held it in 10 quarters since. The position peaked at $18.2M in Q3 2025. 179 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Dmitry Balyasny held 24,201 shares of Oric Pharmaceuticals worth $262K as of Q2 2026.
  • Dmitry Balyasny sold 499,589 Oric Pharmaceuticals shares in Q2 2026, an estimated $4.53M.
  • Oric Pharmaceuticals made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #2746 holding.
  • Dmitry Balyasny first reported a position in Oric Pharmaceuticals in Q3 2022 and has held it in 10 quarters since.
  • Dmitry Balyasny's Oric Pharmaceuticals position peaked at $18.2M in Q3 2025.
  • 179 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.